Q901

(Synonyms: CDK7-IN-21)

Q901 (CDK7-IN-21) is a selective covalent ATP-competitive CDK7 inhibitor with an IC50 value of 10 nM against human CDK7. Q901 inhibits MYC/E2F-dependent oncogenic transcription, the RNAPII transition from initiation to elongation, and DNA damage repair, stabilizes TOP1-DNA protein crosslinks, and induces DNA damage. Q901 sensitizes tumors to topoisomerase I inhibitors and TOP1 inhibitor-based antibody-drug conjugates. Q901 shows additive or synergistic tumor growth inhibition in solid tumor models in combination with PARP inhibitors, SERDs, ER PROTAC degraders, or anti-PD-1 antibodies. Q901 can be used for research on cancers such as ovarian cancer and lung cancer.

For research use only. We do not sell to patients.

  • CAS No.: 2766124-39-2
  • Formula: C33H36FN9O2
  • Molecular Weight:609.70
  • Storage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Protocols
  • Purity & Documentation
  • References
  • Help & FAQs
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00